Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04632784
Other study ID # AP01000816
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 12, 2021
Est. completion date July 2025

Study information

Verified date February 2022
Source Ophtec BV
Contact Erwin Bouwman, MSc
Phone +31 (0)6 83246222
Email study@ophtec.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical trial is to evaluate the effectiveness and safety of the multifocal Artiflex Presbyopic intraocular lens.


Description:

The study is a prospective, open-label, single-arm, and multicentre clinical investigation with three years of follow-up. Artiflex Presbyopic is a phakic intraocular lens to be implanted in the anterior chamber, intended for adult subjects and indicated for the optical correction of presbyopia and spherical error requiring a correction. The results of this study will be used for CE-approval and registration as well as marketing purposes.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date July 2025
Est. primary completion date July 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Presbyopic adult - Potential for binocular vision - Subject wishes to be spectacle independent for near and far vision - Refractive error that can be corrected with correction at PIOL plane from +2.0 to -15.0 D - Subject requiring a presbyopic correction - Patients with reading glasses of minimum +1D - Stable refraction (±0.75 D), as expressed by manifest refraction spherical equivalent (MRSE) for a minimum of 12 months prior to surgery, verified by consecutive refractions and/or medical records or prescription history - Expected best-corrected visual acuity of 0.2 logMAR (0.63 Snellen decimal) or better after lens implantation - Current contact lens wearer should demonstrate stable refraction (± 0.5 D), expressed as subjective refraction spherical equivalent, on two consecutive examination dates performed at least 7 days apart. Before the first refraction, the contact lens wearer should not have worn lenses for at least 2 weeks in case of rigid and toric contact lenses, or 3 days for spherical soft contact lenses. - Any subject, who is expected to have a residual postoperative cylindrical refractive error of below 0.75 D - Ability to give informed consent - Availability, willingness and sufficient cognitive awareness and physical ability to comply with examination procedures throughout the entire duration of the study Exclusion Criteria: Pre-existing pathology or physiology which may be aggravated by the implant or where the implant may interfere with the possibility of examining or treating disease: • Preoperative ocular or systemic condition or medication use that would be expected to present undue risk to the subject, that can predispose for future complications or confound the outcome(s) of the study. E.g. the systemic use of alpha-1a adrenergic receptor antagonists was suggested to increase the occurrence of intraoperative floppy iris syndrome, alter iris morphology - or more specifically reduce iris thickness at the site of potential IOL enclavation - and increase postoperative endothelial cell loss. - Previous ocular surgery which might affect the outcome of the study - Concurrent participation or participation during the last 30 days in another drug or device investigation - Secondary surgical procedure planned during the first 6 months of the study (e.g. laser treatment to correct astigmatism) - Amblyopia - Preoperative anterior chamber depth measurement of below 3.0 mm for subjects < 40 years old and 2.8 mm for subjects > 40 years old. Anterior chamber depth is being measured from corneal endothelium to the anterior pole of the crystalline lens. This will result in a critical distance between PIOL and endothelium of 1.5 mm or more as simulated with anterior segment imaging. - White-to-white smaller than 10.5 mm - Subjects not meeting the age specific minimum preoperative endothelial cell density as defined below: 31 to 35 years of age 2400 cells/mm2; 36 to 45 years of age 2200 cells/mm2; > 45 years of age 2000 cells/mm2 - Corneas with high rates of polymegethism (a coefficient of variation over 0.40) and pleomorphism (the presence of less than 50% hexagonal cells). - Abnormal iris (e.g. convex, bulging or volcano shaped iris) - Crystalline lens rise of 600 µm or more - Abnormal cornea (keratoconus, opaque cornea, corneal scars, post corneal transplant, corneal dystrophy, or other) - Ocular surface conditions which might influence the quality of vision and affect the outcome of the study - Abnormal pupil (e.g. nonreactive, fixed) - Ectopic pupil - Pupil in photopic light conditions smaller than 2.6 mm - Pupil in scotopic light conditions greater than 7.0 mm - High preoperative intraocular pressure (>21 mm Hg) - Cataract of any grade - Glaucoma or family history of glaucoma (dependent on the evaluation of physician) - Diabetes or diabetic retinopathy - Acute or chronic inflammation - Chronic or recurrent uveitis or family history of the same condition - Retinal detachments or family history of retinal detachments - Corticosteroid responder - Pregnant or nursing - Aged under 18

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Artiflex Presbyopic implantation
Implantation of iris-fixated multifocal Artiflex Presbyopic IOL

Locations

Country Name City State
Korea, Republic of GM st. Mary's Eye clinic Busan
Korea, Republic of Seoul ST. Mary's Hospital Seoul
Korea, Republic of SU Yonsei Eye Clinic Seoul
Korea, Republic of Nune Eye Hospital Daegu Seul
Korea, Republic of Nune Eye Hospital Seoul Seul Seoul
Netherlands Maastricht UMC+ Maastricht Limburg
Spain IMO Barcelona Catalonia
Spain ICQO Bilbao Biscay
Spain Instituto oftalmologico de madrid Madrid
Spain Vision Diez Madrid
Spain CIMO Seville

Sponsors (1)

Lead Sponsor Collaborator
Ophtec BV

Countries where clinical trial is conducted

Korea, Republic of,  Netherlands,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement in monocular and binocular uncorrected near visual acuity (UNVA) Percentage of eyes that achieve UNVA of 0.3 logMAR or better
Percentage of eyes that achieve UNVA of 0.0 logMAR or better
3 years
Primary Improvement in monocular and binocular corrected near visual acuity (CNVA) Percentage of eyes that achieve CNVA of 0.3 logMAR or better
Percentage of eyes that achieve CNVA of 0.0 logMAR or better
3 years
Primary Improvement in monocular and binocular distance corrected near visual acuity (DCNVA) Percentage of eyes that achieve DCNVA of 0.3 logMAR or better
Percentage of eyes that achieve DCNVA of 0.0 logMAR or better
3 years
Primary Improvement in monocular and binocular uncorrected intermediate visual acuity (UIVA) Percentage of eyes that achieve UIVA of 0.3 logMAR or better
Percentage of eyes that achieve UIVA of 0.0 logMAR or better
3 years
Primary Improvement in monocular and binocular distance corrected intermediate visual acuity (DCIVA) Percentage of eyes that achieve DCIVA of 0.3 logMAR or better
Percentage of eyes that achieve DCIVA of 0.0 logMAR or better
3 years
Primary Improvement in monocular and binocular uncorrected distance visual acuity (UDVA) Percentage of eyes that achieve UDVA of 0.3 logMAR or better Percentage of eyes that achieve UDVA of 0.0 logMAR or better 3 years
Primary Improvement in monocular and binocular corrected distance visual acuity (CDVA) Percentage of eyes that achieve CDVA of 0.3 logMAR or better
Percentage of eyes that achieve CDVA of 0.0 logMAR or better
3 years
Primary Defocus evaluation Binocular defocus evaluation will be obtained by using the best-corrected distance refraction and then defocusing the image in 0.5 D increments from +1.5 to -5.0 D 3 years
Primary Predictability of the manifest refraction spherical equivalent (MRSE) The absolute difference between the actually obtained MRSE and the target MRSE 3 years
Primary Predictability of the manifest refraction spherical equivalent (MRSE) The percentage of eyes that achieves a MRSE of less than or equal to 0.5 D difference between the actual and target MRSE 3 years
Primary Predictability of the manifest refraction spherical equivalent (MRSE) The percentage of eyes that achieves a MRSE of less than or equal to 1.0 D difference between the actual and target MRSE 3 years
Primary Stability of manifest refraction spherical equivalent (MRSE) Mean change in MRSE between visits as determined by a paired analysis 3 years
Primary Stability of manifest refraction spherical equivalent (MRSE) The percentage of eyes that achieves a change in MRSE of less than or equal to 0.5 D between two consecutive refraction measurements 3 years
Primary Stability of manifest refraction spherical equivalent (MRSE) The percentage of eyes that achieves a change in MRSE of less than or equal to 1.0 D between two consecutive refraction measurements 3 years
Primary Evaluation of visual disturbances using a validated questionnaire Assessing the percentage of subjects who experience different visual disturbances, by means of questionnaire 3 years
Primary Evaluation of visual disturbances using a validated questionnaire Assessing the occurrence of the different visual disturbances by means of questionnaire 3 years
Primary Evaluation of visual disturbances using a validated questionnaire Assessing the severity of the different visual disturbances by means of questionnaire 3 years
Primary Evaluation of visual disturbances using a validated questionnaire Assessing the bothersomeness of the different visual disturbances by means of questionnaire 3 years
Primary Evaluation of visual disturbances using a validated questionnaire Assessing the time of onset of visual disturbances by means of questionnaire 3 years
Primary Satisfaction questionnaire Percentage of subjects that is satisfied with the overall procedure
Percentage of subjects that is satisfied with uncorrected near vision
Percentage of subjects that is satisfied with uncorrected intermediate vision
Percentage of subjects that is satisfied with uncorrected distance vision
3 years
Primary Endothelial cell density Comparison of the preoperative and postoperative endothelial cell density 3 years
Primary Endothelial cell density Endothelial cell loss over time 3 years
Primary Endothelial cell density Additionally, a comparison between the scientific literature reported naturally occurring endothelial cell loss over time (approx. 0.6% per year; Bourne et al., 1997) and the study observed cell loss will be performed 3 years
Primary Adverse event (AEs) / complication rates Cumulative numbers of adverse events, e.g. cystoid macular edema (CME), hypopyon, endophthalmitis, lens dislocation, pupillary block, retinal detachment, necessary secondary surgical interventions
Cumulative numbers of adverse events persistently present, e.g. corneal stroma edema, cystoid macular edema, iritis, raised intraocular pressure (IOP) requiring treatment, lens deposits
The occurrence of adverse events will be compared to and should not exceed the reference safety and performance endpoint (SPE) rates as defined by ISO 11979-7:2018, Annex E, table E.1
3 years
See also
  Status Clinical Trial Phase
Recruiting NCT04923841 - Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine N/A
Active, not recruiting NCT04080128 - Examination of Myopia Progression and Soft Bifocal Contact Lens Myopia Control N/A
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Completed NCT04604405 - Effects of 650nm Low Energy Light on Human Retina and Choroid Microcirculation N/A
Recruiting NCT05594719 - The Effect of Sun-like Spectrum With Different Spectrum Composition on Retinal Blood Flow N/A
Completed NCT05594732 - The Effects of Different Outdoor Light Exposure Modes on Retinal Blood Flow N/A
Completed NCT04492397 - Comparing The Performance Of Two Different Daily Disposable Lenses (MIKI) N/A
Completed NCT04536571 - Vision Stability and Preference for Soft Toric vs. Soft Spherical Contact Lenses N/A
Completed NCT06046209 - Comparing a Monthly Replacement Lens Versus a Daily Disposable Lens N/A
Recruiting NCT06344572 - Pivotal Study of SAT-001 in Treatment of Pediatric Patient With Myopia Phase 3
Recruiting NCT05611294 - Contralateral Study of Topography Guided LASIK Versus Small Incision Lenticule Extraction N/A
Completed NCT05656885 - Clinical Evaluation of Two Frequent Replacement Soft Spherical Contact Lenses N/A
Active, not recruiting NCT05534022 - Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression. N/A
Completed NCT03934788 - the Clinical Performance of the Oxysoft Daily Disposable Silicone Hydrogel Soft Contact Lens N/A
Completed NCT03701516 - Clinical Evaluation of Etafilcon A Contact Lenses Using a Novel Molding Process 2 N/A
Completed NCT05538754 - Post-Market Evaluation of the EVO ICL N/A
Completed NCT03139201 - Clinical Performance of the OxyAqua Daily Disposable Silicone Hydrogel Soft Contact Lens N/A
Completed NCT02555722 - Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear N/A
Not yet recruiting NCT06009458 - Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear N/A
Recruiting NCT05548478 - Corneal Endothelial Cell Injury Induced by Mitomycin-C N/A